1. Home
  2. TRDA vs TCX Comparison

TRDA vs TCX Comparison

Compare TRDA & TCX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • TRDA
  • TCX
  • Stock Information
  • Founded
  • TRDA 2016
  • TCX 1992
  • Country
  • TRDA United States
  • TCX Canada
  • Employees
  • TRDA N/A
  • TCX N/A
  • Industry
  • TRDA Biotechnology: Pharmaceutical Preparations
  • TCX EDP Services
  • Sector
  • TRDA Health Care
  • TCX Technology
  • Exchange
  • TRDA Nasdaq
  • TCX Nasdaq
  • Market Cap
  • TRDA 222.5M
  • TCX 203.7M
  • IPO Year
  • TRDA 2021
  • TCX 1996
  • Fundamental
  • Price
  • TRDA $5.84
  • TCX $18.35
  • Analyst Decision
  • TRDA Strong Buy
  • TCX
  • Analyst Count
  • TRDA 3
  • TCX 0
  • Target Price
  • TRDA $25.67
  • TCX N/A
  • AVG Volume (30 Days)
  • TRDA 350.3K
  • TCX 18.9K
  • Earning Date
  • TRDA 11-04-2025
  • TCX 11-06-2025
  • Dividend Yield
  • TRDA N/A
  • TCX N/A
  • EPS Growth
  • TRDA N/A
  • TCX N/A
  • EPS
  • TRDA N/A
  • TCX N/A
  • Revenue
  • TRDA $79,476,000.00
  • TCX $378,467,000.00
  • Revenue This Year
  • TRDA N/A
  • TCX N/A
  • Revenue Next Year
  • TRDA N/A
  • TCX N/A
  • P/E Ratio
  • TRDA N/A
  • TCX N/A
  • Revenue Growth
  • TRDA N/A
  • TCX 7.88
  • 52 Week Low
  • TRDA $4.93
  • TCX $13.27
  • 52 Week High
  • TRDA $21.79
  • TCX $23.38
  • Technical
  • Relative Strength Index (RSI)
  • TRDA 51.80
  • TCX 46.38
  • Support Level
  • TRDA $5.82
  • TCX $18.11
  • Resistance Level
  • TRDA $6.90
  • TCX $19.10
  • Average True Range (ATR)
  • TRDA 0.36
  • TCX 0.44
  • MACD
  • TRDA 0.07
  • TCX -0.01
  • Stochastic Oscillator
  • TRDA 45.88
  • TCX 35.00

About TRDA Entrada Therapeutics Inc.

Entrada Therapeutics Inc is a clinical-stage biopharmaceutical company. It aims to transform the lives of patients by establishing a new class of medicines that engage intracellular targets that have long been considered inaccessible. The Company's Endosomal Escape Vehicle (EEV)-therapeutics are designed to enable the efficient intracellular delivery into a variety of organs and tissues, resulting in an improved therapeutic index and protein-based programs for the potential treatment of neuromuscular and ocular diseases, among others. Its oligonucleotide programs are in development for the potential treatment of people living with Duchenne, which are exon 44, 45, 50, and 51 skipping amenable. It has partnered to develop a clinical-stage program, VX-670, for myotonic dystrophy type 1.

About TCX Tucows Inc.

Tucows Inc is a corporate parent, allocating capital and providing efficient shared services to its three businesses. The Company offers Mobile Service Enabler (MSE) solutions, as well as professional services to other retail mobile providers. The Company is also a distributor of Internet services, including domain name registration, digital certificates, and email. It provides these services through an Internet-based distribution network of Internet Service Providers, web hosting companies, and other providers of Internet services to end-users. It operates in three segments: Ting, Wavelo, and Tucows Domains. It generates the majority of its revenue from Tucows Domains. Geographically company operates in USA, Canada and Europe.

Share on Social Networks: